FDA Requests Input on Use of AI for Diabetes Detection
Summary
The Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) issued a Request for Information (RFI) seeking information on how AI/ML may help with early detection of risk factors for type 2 diabetes, prediabetes and undiagnosed diabetes. The RFI includes several questions targeting identifying ongoing efforts to advance early detection of diabetes, including how technologies capture biomarkers and how they can be used to ensure health equity. The public comment period will end on January 31, 2024.
Impacted Sectors
Additional Information
© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.